FOLR1 and ovarian carcinoma: This is consistent with our prior data where we prospectively tested for immunity in both breast and ovarian cancer patients using a panel of FRα-derived peptides representing potential T-cell epitopes.24 In that study, more than 70% of patients demonstrated immunity to at least one FRα peptide.